|本期目录/Table of Contents|

[1]罗晓璐,磨立达,魏振满,等.3 组常用一线抗HIV 药物疗效精确化试验研究[J].传染病信息,2017,06:342-345,383.
 LUO Xiao-lu,MO Li-da*,WEI Zhen-man,et al.Study of curative effect accuracy among3 groups of commonly used anti-HIV drugs[J].Infectious Disease Information,2017,06:342-345,383.
点击复制

3 组常用一线抗HIV 药物疗效精确化试验研究(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2017年06期
页码:
342-345,383
栏目:
专题论著
出版日期:
2017-12-20

文章信息/Info

Title:
Study of curative effect accuracy among3 groups of commonly used anti-HIV drugs
作者:
罗晓璐磨立达魏振满苏国生黄金萍吴景瑜
530023,南宁市第四人民医院检验科(罗晓璐、磨立达、苏国生),艾滋病科(黄金萍);100039 北京,解放军第三〇二医院药学部(魏振满);530002,南宁市兴宁区疾病预防控制中心艾滋病科(吴景瑜)
Author(s):
LUO Xiao-lu MO Li-da* WEI Zhen-man SU Guo-sheng HUANG Jin-ping WU Jing-yu
Clinical Laboratory, the Fourth People’s Hospital of Nanning, 530023, China
关键词:
HIV/AIDS 患者齐多夫定司他夫定替诺福韦疗效
Keywords:
HIV/AIDS patients zidovudine stavudine tenofovir curative effect
分类号:
R512.91
DOI:
10.3969/j.issn.1007-8134.2017.06.007
文献标识码:
A
摘要:
目的 通过动态临床试验分析,对广西地区目前常用的AZT、d4T 及TDF 为主的3 组抗反转录病毒治疗方案进行临床疗效比较。方法 收治HIV/AIDS 患者76 例,分为3 组,AZT 组接受AZT+3TC+EFV 治疗,d4T 组接受d4T+3TC+EFV 治疗,TDF 组接受TDF+3TC+EFV 治疗。对3 组30 个月内新发机会性感染率、免疫重建效果、病毒学应答效果、主要生化指标变化、换药及耐药情况进行动态分析比较。结果 3 组患者经治疗满6 个月时HIV RNA 载量显著下降(P均< 0.05),CD4+ T 淋巴细胞计数显著上升(P 均< 0.05),但是3 组间差异无统计学意义;6 个月以后各组CD4+ T 淋巴细胞计数上升缓慢,12 个月和18 个月时,d4T 组CD4+ T 淋巴细胞计数上升幅度均大于AZT 组和TDF 组(P 均< 0.05);3 组患者治疗满6 个月ALB 显著升高(P 均< 0.05),而后各阶段变化不大;AZT 组、d4T 组、TDF 组随访期间新发机会性感染发生率分别为15.62%、11.53%、27.77%,不良反应换药率分别为12.50%、30.80%、16.67%,但差异均无统计学意义。结论 广西地区3 组常用一线抗HIV 药物方案的治疗效果显著且相似,但d4T 方案因药物不良反应和耐药而换药的发生率较高,应考虑停用。
Abstract:
Objective To compare clinical curative effect of 3 ART regimens in Guangxi region through a dynamic clinicaltrial analysis. Methods Seventy-six HIV/AIDS patients were included in this study and randomly divided into 3 groups. AZT groupwas treated with AZT+3TC+EFV. The d4T group received d4T+3TC+EFV treatment. TDF group received TDF+3TC+EFV treatment.The incidence of opportunistic infections, immune reconstitution, virological response, changes of major biochemical indexes, dressingchange and drug resistance were dynamically analyzed and compared in 3 groups within 30 months. Results The HIV-RNA loadingwas significantly decreased in 3 groups at 6 months of treatment (P < 0.05), while the levels of CD4+ T lymphocytes increasedsignificantly (P < 0.05), but there was no significant difference among 3 groups. After 6 months of treatment, CD4+ T lymphocytesincreased gradually in 3 groups. At 12 and 18 months, the increment of CD4+ T lymphocytes in d4T group was more significant than thatin AZT group and TDF group (P < 0.05). The ALB level in 3 groups increased significantly at 6 months of treatment (P < 0.05), andthen the change was not obvious at subsequent time points. The incidence of opportunistic infections was 15.62% in AZT group, 11.53%in d4T group, 27.77% in TDF group. The dressing change rate was 12.50% in AZT group, 30.80% in d4T group and 16.67% in TDFgroup, respectively, however no significant difference was observed. Conclusions Three first-line anti-HIV drug regimens commonlyused in Guangxi area have significant and similar effects, but the rate of dressing change for d4T regimen is higher due to adverse drugreactions and drug resistance, so this regimen is recommended to withdraw.

参考文献/References

[1] 史继静,张昕,徐若男,等. 细胞治疗与AIDS功能性治愈[J].传染病信息,2015,28(6):265-270.
[2] 杨文杰,樊盼英,梁妍,等. 2008—2013 年河南省艾滋病患者抗病毒治疗对HIV 的抑制效果及其影响因素分析[J]. 中华预防医学杂志,2015,49(1):13-20.
[3] 中华医学会感染病学分会艾滋病学组. 艾滋病诊疗指南(第三版)[J]. 中华传染病杂志,2015,33(10):577-593.
[4] 孙永涛,王临旭. AIDS的高效抗反转录病毒治疗指南解读[J].传染病信息,2010,23 (6):329-332.
[5] 姜明东,夏永惠,曲文才,等. 德州市2005—2015 年艾滋病免费抗病毒治疗效果及影响因素评价[J]. 中国艾滋病性病,2016,22(11):856-859.
[6] Li T, Wu N, Dai Y, et al. Reduced thymic output is a majormechanism of immune reconstitution failure in HIV-infectedpatients after long-term antiretroviral therapy[J]. ClinicalInfectious Diseases, 2011, 53(9):944-951.
[7] 宋映雪,辛若雷,叶军,等. 北京地区未经抗病毒治疗的HIV 感染者HIV-1 毒株耐药基因变异研究[J]. 中国艾滋病性病,2015,21(10):836-838.

备注/Memo

备注/Memo:
[基金项目] 南宁市兴宁区科学研究与技术开发项目(2015A15);十三五国家重大新药创制课题(2017ZX09009070-001-008)
[通信作者] 磨立达,E-mail: 1773398578@qq.com
更新日期/Last Update: 2017-12-20